DINESH

Krishna Institute of Medical Sciences

Industry: Healthcare
Latest CMP 809
Today's Change ▲ 0.19%
52-Week High / Low 851 | 582
Price Date: 14-Aug-2026
Recommendation Sell
Target Price 482
Expected Upside -22.8%
Forecast Horizon 2 Years
Historical CAGR 25.6%
1,000 Invested 05-Jul-2021
Today's Value 3,207
Investment Period 5 Years

Stock Snapshot

Post Results Return
+0.9%
Neutral Market Reaction
1-Year Target Price
477
2-Year Target Price
482
52-Week High / Low
851 / 582
20-Day Return
+2.6%
Market Cap (Cr.)
32,364
Current PE
67.6
P/BV Ratio
14.4
Dividend Yield
Industry PE
57.2

Price Performance

Basis of our Recommendation

Krishna Institute of Medical Sciences (KIMS) is navigating a pivotal phase characterized by aggressive expansion and a focus on operational efficiency. Management's recent commentary highlights strong volume growth in both inpatient and outpatient segments, supported by a successful INR 1,500 crore QIP that has bolstered the balance sheet and reduced debt. However, the company faces margin pressures due to the initial ramp-up costs associated with new facilities, particularly in Maharashtra and Kerala. Despite these challenges, KIMS is optimistic about returning to 30%+ EBITDA margins as occupancy levels stabilize. The healthcare sector's growth trajectory remains favorable, driven by increasing demand for organized healthcare services, although competitive and regulatory challenges persist. Vista's financial outlook reflects moderating revenue growth and ongoing margin pressures, with a fair valuation aligned with intrinsic value. Over the next 12-24 months, KIMS's key opportunities include successful stabilization of new units and expansion into core geographies, while watchpoints include execution risks related to talent acquisition and the time required for new facilities to reach maturity

👍 Why We Like This Stock

  • Strong volume growth in both inpatient and outpatient segments supports revenue stability
  • Successful capital raise has improved liquidity and reduced debt, enhancing financial flexibility
  • Management's focus on operational efficiency and strategic expansion is expected to drive future profitability

Things To Watch Out For

  • Initial ramp-up costs from new facilities are exerting pressure on margins
  • Execution risks related to high employee turnover and competition for talent in non-South Indian markets
  • Potential delays in achieving target occupancy levels in newly commissioned units may hinder short-term performance

Key Parameters

Balance Sheet Strength
Stable Financial Structure
Market Share
Stable
Industry Outlook
Stable
Analyst View
Strong Buy
Dividend History
No Dividend History
FII Holdings
Stable

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 2,498 3,035 3,905 4,354 5,206
Profit Before Tax (Cr.) 457 532 345 146 311
PBT Margin 18.3% 17.5% 883.5% 3.4% 6.0%
Net Profit (Cr.) 341 390 205 110 232
Earnings Per Share 7.9 9.0 5.1 2.7 5.8

Analyst Recommendations

Broker Recommendation Target Price Date
Goldman Sachs ▲ Buy 1,025 19-May-2026
HSBC ▲ Buy 780 21-Apr-2026
ICICI Securities ► Add 885 05-Aug-2026
JMFinancials ▲ Buy 904 21-May-2026
Kotak Securities ▼ Sell 695 19-May-2026
Moneycontrol ▲ Overweight nan 05-Aug-2026
Prabhudas Liladhar ▲ Buy 850 05-Aug-2026
Consensus Recommendation ▲ Strong Buy
Consensus Target 868
Coverage 7 Analysts
Analysts' Viewpoint
KIMS is shifting focus from expansion to optimizing operations, leveraging strong volume growth and a significant bed expansion pipeline for multi-year growth. The recent QIP has strengthened the balance sheet, reducing debt and providing financial flexibility. Analysts highlight successful ramp-ups in new clusters, though profitability is pressured by high ramp-up costs and slower doctor onboarding. Key risks include margin pressure from new capacity additions and potential delays in insurance empanelment. Future catalysts include operational leverage as new hospitals mature and strategic focus on stabilizing occupancy.

Company Overview

Show Company Profile

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers arthroscopy and shoulder, cardiology, cardiothoracic and cardiovascular, organ transplant, medical and surgical gastroenterology, hepatology, orthopaedic, neurology, neurosurgery, nephrology, urology, oncology, pediatric, neonatology, obstetrics and gynaecology, fertility, dental science, emergency and critical care, vascular, rehabilitation and physiotherapy services. It also provides pulmonology, diagnostic and imaging, ophthalmology, ENT, rheumatology and clinical immunology, internal medicine, interventional radiology, diabetology, endocrinology, general surgery, infectious disease, dermatology, thoracic surgery, psychiatry, plastic and reconstructive surgery, transfusion medicine, clinical psychology, anesthesiology, and tele medicine services. In addition, the company operates clinical immunology allergy, bone marrow transplantation, hair transplant, andrology, fertility, alzheimer, arthroscopy, bone and joint, breast, dialysis, female urology, IUI, IVF, joint replacement, kidney health and transplant, ICU, spine, stroke, TAVR/TAVI, hepatobiliary surgery, and trauma centers, as well as pain and wellness clinics. Further, it provides bariatric, thoracic, oral maxillofacial, and endovascular surgery services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.